Writing the Worldwide Marketing Authorisation Status Section in a PBRER

The Worldwide Marketing Authorisation Status section establishes the regulatory footprint in which the PBRER should be interpreted. It tells the reader where and how the medicinal product has been authorised, and which important changes to that status matter to the current benefit-risk assessment. It is context, not a substitute for the safety-actions or benefit-risk sections.

Purpose and Regulatory Framework

The PBRER structure is defined by ICH E2C(R2) and implemented for EU PSURs through Commission Implementing Regulation (EU) No 520/2012 and GVP Module VII — Periodic safety update report (Rev. 1).

Worldwide authorisation status helps the assessor understand the maturity and geographic breadth of the product's marketed experience. It can also identify important regulatory changes such as first authorisations, extensions to major markets, safety-related suspensions or withdrawals, and other changes that materially affect interpretation of cumulative exposure and benefit-risk.

International Birth Date

The international birth date (IBD) provides the common lifecycle reference point used in periodic reporting. It generally corresponds to the date of the first marketing authorisation for any product containing the active substance granted to any company in any country, as defined in the applicable ICH framework.

The author should distinguish the IBD from:

• the first EU authorisation date;
• the first authorisation held by the current MAH;
• the first commercial launch date; and
• the date on which a particular indication or formulation was authorised.

These dates can differ substantially.

What the Section Should Convey

Depending on the product and reporting period, the section may need to establish:

• the IBD or other applicable lifecycle reference;
• the countries or major regions where the product is authorised;
• important new authorisations during the interval;
• significant restrictions, suspensions, revocations or withdrawals;
• major indication or formulation differences where relevant; and
• whether important authorisation-status changes were safety-driven.

The objective is not to reproduce every administrative variation.

Authorised Is Not the Same as Marketed

A medicinal product can be authorised but not commercially marketed, temporarily unavailable, discontinued commercially or supplied only in selected presentations. These states should not be used interchangeably.

Where marketing status materially affects exposure interpretation, the report should distinguish regulatory authorisation from actual commercial availability. A commercial discontinuation should not be described as a safety withdrawal unless safety was genuinely the reason.

Safety-Related Versus Non-Safety Changes

An authorisation may be withdrawn or not renewed for commercial, manufacturing, strategic or administrative reasons. Such events can be relevant to worldwide status without representing a safety action.

Where a suspension, restriction, revocation or withdrawal is taken for safety reasons, the event should also reconcile with the PBRER's Actions Taken for Safety Reasons and later benefit-risk discussion.

The report should therefore describe both the regulatory event and its reason accurately.

Geographic Detail Should Be Proportionate

A mature product may be authorised in dozens of countries. A country-by-country prose history can obscure the few developments that matter scientifically.

Tables are often more efficient for broad status information, while narrative should focus on major changes, unusual regional differences and events relevant to the safety assessment.

The level of detail should be sufficient for the assessor to understand the global regulatory context without turning the section into a regulatory database export.

Building the Authorisation-Status Dataset

The writing team should establish the source of truth before drafting. Depending on the organisation, relevant evidence may come from regulatory-information management systems, approved authorisation records, affiliate confirmations and controlled product master data.

Important questions include:

• Which legal entities hold relevant marketing authorisations?
• Which countries and presentations are within the PBRER scope?
• Were any first authorisations granted during the interval?
• Did any authorisation cease, and why?
• Were there important indication restrictions or extensions?
• Were changes temporary or permanent?
• Does authorisation status reconcile with exposure and Actions Taken for Safety Reasons?

The PBRER does not require the author to reproduce the internal regulatory database. It requires an accurate, intelligible summary.

Multiple Marketing Authorisation Holders and Licensing Arrangements

Global products may be marketed by affiliates, licensees or independent partners. These arrangements can produce different authorisation dates, product names and regulatory statuses.

The scientific focus should remain on the medicinal product covered by the report. Commercial contract details should be included only where they are necessary to understand the regulatory footprint or differences in safety action.

Where the MAH lacks complete information about an independent partner's territories, the report should use verified information and describe material limitations rather than create false precision.

Acquisitions and Divestments

Ownership changes do not reset the scientific lifecycle of the active substance. After acquisition, the current MAH may inherit products with long pre-acquisition histories and an IBD far earlier than its own authorisation date.

The section should therefore preserve the appropriate lifecycle reference while explaining major ownership or scope transitions only when needed to understand the current report.

Divestment similarly changes responsibility without necessarily changing the intrinsic safety profile. If territories leave the reporting scope, the author should ensure that cumulative data and exposure are interpreted consistently with the applicable reporting framework.

New Indications, Routes and Formulations

An important extension of use can change the population exposed and therefore the context of later safety evaluation. For example, movement from a specialist adult indication into a paediatric population may materially alter exposure patterns and areas of uncertainty.

Such changes should be described where they help the reader understand:

• why exposure increased;
• why new safety data became available;
• why a particular population appears in risk evaluation; or
• why benefit-risk differs between authorised uses.

The authorisation-status section should state the regulatory development; the detailed clinical implications belong later.

Suspensions, Revocations and Withdrawals

The terminology should match the actual regulatory event. Suspension, revocation, non-renewal and withdrawal are not interchangeable.

For a safety-driven event, useful context includes:

• jurisdiction;
• affected indication, formulation or authorisation where relevant;
• timing;
• whether the measure is temporary or permanent; and
• the safety reason at a level sufficient to connect to later evaluation.

Detailed scientific evidence should not be duplicated here.

Regional Differences

Different authorities may reach different decisions or implement them at different times. The PBRER should describe material differences objectively.

For example, one authority may restrict an indication while another requests additional data before deciding. The author should not imply that either position is globally adopted. The current regulatory status at the DLP should be clear.

Relationship With Exposure

Authorisation status is not itself exposure, but it helps explain exposure. A newly authorised market may have no meaningful commercial uptake by the DLP; conversely, a long-authorised product may have substantial established use.

The exposure section should therefore use actual or estimated utilisation data rather than infer exposure directly from the number of countries authorised.

Relationship With Safety Actions

When a regulatory-status change results from a safety concern, three sections may each have a distinct role:

• Worldwide Marketing Authorisation Status: what changed in the authorisation footprint.
• Actions Taken for Safety Reasons: what safety-driven regulatory action occurred.
• Risk/Benefit-Risk sections: why the evidence justified the action and what it means scientifically.

Cross-section consistency is more important than verbatim repetition.

Illustrative Example

Suppose a medicinal product is authorised in 45 countries. During the interval it receives its first paediatric authorisation in two major markets, is commercially discontinued for non-safety reasons in three small markets and has one indication temporarily suspended in one country following a safety review.

A weak section would list all 45 countries and describe every status change equally.

A stronger section would provide the global status efficiently, highlight the new paediatric authorisations because they change the exposed population, distinguish the commercial discontinuations from safety action, and explain the temporary safety-driven suspension with a cross-reference to the relevant safety evaluation.

Potential Writing Failure Modes

The following are illustrative writing failures, not inspection findings.

Practical Review Checklist

1. Is the IBD or other applicable lifecycle reference verified?
2. Is authorisation distinguished from commercial marketing?
3. Are significant interval authorisations identified?
4. Are safety-driven and non-safety status changes distinguished?
5. Are suspension, revocation, withdrawal and non-renewal used accurately?
6. Is geographic detail proportionate?
7. Are important indication, route or population changes clear?
8. Are partner and MAH differences described only where material?
9. Does the section reconcile with exposure information?
10. Do safety-related status changes reconcile with Actions Taken for Safety Reasons?
11. Are regional differences represented accurately at the DLP?
12. Does later benefit-risk evaluation address material authorisation restrictions where relevant?

Relationship With Other QPPV.com PBRER Articles

For overall report architecture see [[understanding-the-structure-of-a-pbrer]]. Safety-driven regulatory measures are covered in [[writing-the-actions-taken-for-safety-reasons-section]], while their scientific implications flow into [[writing-the-evaluation-of-risks-and-new-information-section-in-a-pbrer]] and [[writing-the-integrated-benefit-risk-evaluation-section-in-a-pbrer]].

Key Takeaways

Worldwide authorisation status gives the regulatory context for the PBRER; it should not become a full regulatory-affairs history.

The IBD should be verified and distinguished from EU approval, company acquisition and commercial launch dates.

Authorisation, marketing and exposure are related but different concepts.

Safety-driven withdrawals, suspensions and restrictions should be identified accurately and reconciled with the report's safety-action and benefit-risk sections.

Geographic detail should be proportionate to scientific relevance.

References

1. International Council for Harmonisation. ICH E2C(R2): Periodic Benefit-Risk Evaluation Report (PBRER). Step 4, 15 November 2012.
2. International Council for Harmonisation. ICH E2C(R2) Questions and Answers. Last update 31 March 2014.
3. European Medicines Agency. GVP Module VII — Periodic safety update report (Rev. 1). EMA/816292/2011 Rev. 1.
4. European Medicines Agency. Periodic safety update reports (PSURs). Current procedural guidance.
5. European Union. Commission Implementing Regulation (EU) No 520/2012, as amended.
6. European Union. Directive 2001/83/EC, as amended.
7. European Union. Regulation (EC) No 726/2004, as amended.

Regulatory Note

This article explains authoring of worldwide marketing authorisation status within the PBRER/PSUR framework. It does not create a requirement for a particular country table, regulatory database export or internal approval structure. As of 9 September 2026, GVP Module VII Rev. 1 remains the published EMA module; live submission requirements should be checked against current procedural guidance.